Login / Signup

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.

Mona KafkaThomas BurtscherJosef FritzMaximilian SchmitzJasmin BekticMichael LadurnerWolfgang HorningerIsabel Heidegger
Published in: World journal of urology (2022)
We observed a trend towards a higher benefit of NHT as first-line treatment compared to Docetaxel in men with mHSPC. Of note, a PSA-Nadir ≤ 0.05 ng/ml or a TSH-increase during therapy were predictors for therapy response.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • squamous cell carcinoma
  • small cell lung cancer
  • bone marrow